Kissei Pharmaceutical Co., Ltd. (TYO:4547)
Japan · Delayed Price · Currency is JPY 4,185.00
+60.00 (1.45%)
Jul 16, 2025, 3:30 PM JST
Kissei Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 88,330 | 75,579 | 67,493 | 65,381 | 69,044 | Upgrade | |
Revenue Growth (YoY) | 16.87% | 11.98% | 3.23% | -5.30% | 9.19% | Upgrade |
Cost of Revenue | 44,265 | 38,238 | 35,118 | 34,143 | 36,321 | Upgrade |
Gross Profit | 44,065 | 37,341 | 32,375 | 31,238 | 32,723 | Upgrade |
Selling, General & Admin | 22,179 | 20,790 | 20,289 | 19,923 | 19,607 | Upgrade |
Research & Development | 12,889 | 9,474 | 10,391 | 10,363 | 9,626 | Upgrade |
Other Operating Expenses | 129 | 143 | 149 | 137 | 149 | Upgrade |
Operating Expenses | 38,291 | 33,324 | 33,518 | 32,640 | 31,217 | Upgrade |
Operating Income | 5,774 | 4,017 | -1,143 | -1,402 | 1,506 | Upgrade |
Interest Expense | -21 | -18 | -20 | -23 | -23 | Upgrade |
Interest & Investment Income | 1,449 | 1,318 | 1,402 | 1,586 | 1,272 | Upgrade |
Currency Exchange Gain (Loss) | -229 | -103 | 186 | -60 | -130 | Upgrade |
Other Non Operating Income (Expenses) | 29 | 35 | 57 | 280 | 131 | Upgrade |
EBT Excluding Unusual Items | 7,002 | 5,249 | 482 | 381 | 2,756 | Upgrade |
Gain (Loss) on Sale of Investments | 11,719 | 9,119 | 13,133 | 16,161 | 4,727 | Upgrade |
Gain (Loss) on Sale of Assets | -215 | 80 | 63 | -35 | -10 | Upgrade |
Asset Writedown | -2,895 | - | - | - | - | Upgrade |
Other Unusual Items | -2 | -1 | 1 | -1 | 3 | Upgrade |
Pretax Income | 15,609 | 14,447 | 13,679 | 16,506 | 7,476 | Upgrade |
Income Tax Expense | 3,634 | 3,159 | 3,046 | 3,475 | 2,098 | Upgrade |
Earnings From Continuing Operations | 11,975 | 11,288 | 10,633 | 13,031 | 5,378 | Upgrade |
Minority Interest in Earnings | -14 | -128 | -105 | -110 | -93 | Upgrade |
Net Income | 11,961 | 11,160 | 10,528 | 12,921 | 5,285 | Upgrade |
Net Income to Common | 11,961 | 11,160 | 10,528 | 12,921 | 5,285 | Upgrade |
Net Income Growth | 7.18% | 6.00% | -18.52% | 144.48% | 87.61% | Upgrade |
Shares Outstanding (Basic) | 44 | 45 | 46 | 46 | 47 | Upgrade |
Shares Outstanding (Diluted) | 44 | 45 | 46 | 46 | 47 | Upgrade |
Shares Change (YoY) | -3.62% | -1.86% | - | -1.18% | -0.11% | Upgrade |
EPS (Basic) | 274.20 | 246.58 | 228.30 | 280.19 | 113.25 | Upgrade |
EPS (Diluted) | 274.20 | 246.58 | 228.30 | 280.19 | 113.25 | Upgrade |
EPS Growth | 11.20% | 8.01% | -18.52% | 147.41% | 87.81% | Upgrade |
Free Cash Flow | 2,014 | -2,878 | -8,782 | 44 | -3,473 | Upgrade |
Free Cash Flow Per Share | 46.17 | -63.59 | -190.44 | 0.95 | -74.42 | Upgrade |
Dividend Per Share | 100.000 | 82.000 | 80.000 | 56.000 | 54.000 | Upgrade |
Dividend Growth | 21.95% | 2.50% | 42.86% | 3.70% | 3.85% | Upgrade |
Gross Margin | 49.89% | 49.41% | 47.97% | 47.78% | 47.39% | Upgrade |
Operating Margin | 6.54% | 5.32% | -1.69% | -2.14% | 2.18% | Upgrade |
Profit Margin | 13.54% | 14.77% | 15.60% | 19.76% | 7.66% | Upgrade |
Free Cash Flow Margin | 2.28% | -3.81% | -13.01% | 0.07% | -5.03% | Upgrade |
EBITDA | 10,389 | 8,271 | 2,966 | 2,328 | 4,654 | Upgrade |
EBITDA Margin | 11.76% | 10.94% | 4.40% | 3.56% | 6.74% | Upgrade |
D&A For EBITDA | 4,615 | 4,254 | 4,109 | 3,730 | 3,148 | Upgrade |
EBIT | 5,774 | 4,017 | -1,143 | -1,402 | 1,506 | Upgrade |
EBIT Margin | 6.54% | 5.32% | -1.69% | -2.14% | 2.18% | Upgrade |
Effective Tax Rate | 23.28% | 21.87% | 22.27% | 21.05% | 28.06% | Upgrade |
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.